gvtcx

NHS Framework for the Midlands and East, Branded Medicines - Tranche B

NHS England Published 30 Apr 2021 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£228,156,862
Statuscomplete
Category (CPV) 33600000
RegionEast Midlands, East of England, London, South East, South West, West Midlands
Deadline5 Nov 2020
Contract start1 Mar 2021
Contract end28 Feb 2023
Procedureopen
SME suitableYes
OCIDocds-b5fd17-a3813112-7a5b-461b-9e42-ccdb117c93ef

Awards (37)

This procurement was awarded to 37 suppliers. Values shown are per-award; the notice total is £228,156,862.

SupplierValueDateStatus
Accord-UK Ltd shared £228,156,862 25 Jan 2021 active
AMGEN LIMITED shared £228,156,862 25 Jan 2021 active
Astrazeneca Plc shared £228,156,862 25 Jan 2021 active
AVENTIS PHARMA LIMITED shared £228,156,862 25 Jan 2021 active
Bayer Ltd shared £228,156,862 25 Jan 2021 active
Biogen shared £228,156,862 25 Jan 2021 active
Bristol Myers Squibb shared £228,156,862 25 Jan 2021 active
Celltrion Healthcare United Kingdom Limited shared £228,156,862 25 Jan 2021 active
CST Pharma Limited shared £228,156,862 25 Jan 2021 active
Daiichi Sankyo UK Ltd shared £228,156,862 25 Jan 2021 active
Day Lewis Medical Ltd shared £228,156,862 25 Jan 2021 active
Dr.Reddy's Laboratories (UK) Limited shared £228,156,862 25 Jan 2021 active
Eli Lilly & Company Ltd shared £228,156,862 25 Jan 2021 active
Ferring Pharmaceuticals Ltd shared £228,156,862 25 Jan 2021 active
Gedeon Richter UK Ltd shared £228,156,862 25 Jan 2021 active
Gilead Sciences Limited shared £228,156,862 25 Jan 2021 active
Ipsen shared £228,156,862 25 Jan 2021 active
Janssen-Cilag Ltd shared £228,156,862 25 Jan 2021 active
LEO Pharma shared £228,156,862 25 Jan 2021 active
Merck Serono Limited shared £228,156,862 25 Jan 2021 active
Merck Sharpe & Dohme (UK) Limited shared £228,156,862 25 Jan 2021 active
Mylan shared £228,156,862 25 Jan 2021 active
Napp Pharmaceuticals Ltd shared £228,156,862 25 Jan 2021 active
Novartis Pharmaceuticals UK Ltd shared £228,156,862 25 Jan 2021 active
Novo Nordisk shared £228,156,862 25 Jan 2021 active
Organon Pharmaceuticals shared £228,156,862 25 Jan 2021 active
Pfizer Ltd shared £228,156,862 25 Jan 2021 active
Roche Products Ltd shared £228,156,862 25 Jan 2021 active
ROVI Biotech Ltd shared £228,156,862 25 Jan 2021 active
Sandoz Ltd shared £228,156,862 25 Jan 2021 active
Sobi (Swedish Orphan Biovitrum Ltd) shared £228,156,862 25 Jan 2021 active
Takeda UK Ltd shared £228,156,862 25 Jan 2021 active
Techdow Pharma England Ltd shared £228,156,862 25 Jan 2021 active
Teva UK Limited shared £228,156,862 25 Jan 2021 active
Thornton and Ross Ltd shared £228,156,862 25 Jan 2021 active
UCB Pharma Ltd shared £228,156,862 25 Jan 2021 active
UL Global Pharma shared £228,156,862 25 Jan 2021 active

description

NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
25 Nov 2020 Tender (tender) · 0770ff43-43ee-4d58-b4cd-6f7c7bebe450-396054
30 Apr 2021 Award update (awardUpdate) · de189c9b-416c-411b-8b1f-873c66578cb9-433023

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.